About telesis bio inc - TBIO
Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.
TBIO At a Glance
Telesis Bio, Inc.
10421 Wateridge Circle
San Diego, California 92121-2993
| Phone | 1-858-228-4115 | Revenue | 27.51M | |
| Industry | Miscellaneous Commercial Services | Net Income | -47,724,000.00 | |
| Sector | Commercial Services | 2023 Sales Growth | 0.27% | |
| Fiscal Year-end | 12 / 2024 | Employees | 147 | |
| View SEC Filings |
TBIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.433 |
| Price to Book Ratio | 50.40 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.812 |
| Enterprise Value to Sales | 2.045 |
| Total Debt to Enterprise Value | 0.611 |
TBIO Efficiency
| Revenue/Employee | 187,136.054 |
| Income Per Employee | -324,653.061 |
| Receivables Turnover | 4.596 |
| Total Asset Turnover | 0.363 |
TBIO Liquidity
| Current Ratio | 3.709 |
| Quick Ratio | 3.217 |
| Cash Ratio | 2.362 |
TBIO Profitability
| Gross Margin | 46.705 |
| Operating Margin | -127.776 |
| Pretax Margin | -173.398 |
| Net Margin | -173.485 |
| Return on Assets | -62.889 |
| Return on Equity | -125.419 |
| Return on Total Capital | -74.664 |
| Return on Invested Capital | -73.733 |
TBIO Capital Structure
| Total Debt to Total Equity | 116.392 |
| Total Debt to Total Capital | 53.788 |
| Total Debt to Total Assets | 48.828 |
| Long-Term Debt to Equity | 13,679.832 |
| Long-Term Debt to Total Capital | 50.937 |